Cargando…
A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly
OBJECTIVE: To evaluate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of acromegaly. DESIGN AND PATIENTS: Ninety-eight previously untreated acromegalics were recruited into this prospective multicentre study. A total of 68 patients...
Autores principales: | Mercado, Moises, Borges, Fatima, Bouterfa, Hakim, Chang, Tien-Chun, Chervin, Alberto, Farrall, Andrew J, Patocs, Attila, Petersenn, Stephan, Podoba, Jan, Safari, Mitra, Wardlaw, Joanna |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1974838/ https://www.ncbi.nlm.nih.gov/pubmed/17465997 http://dx.doi.org/10.1111/j.1365-2265.2007.02825.x |
Ejemplares similares
-
Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly
por: Tutuncu, Yasemin, et al.
Publicado: (2011) -
Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers
por: Tiberg, Fredrik, et al.
Publicado: (2015) -
Octreotide-Resistant Acromegaly: Challenges and Solutions
por: Corica, Giuliana, et al.
Publicado: (2020) -
Pharmacokinetic and technical comparison of Sandostatin(® )LAR(® )and other formulations of long-acting octreotide
por: Petersen, Holger, et al.
Publicado: (2011) -
Everolimus in combination with octreotide LAR in thymic atypical carcinoid
por: Sakane, Tadashi, et al.
Publicado: (2023)